Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide ...

8 September 2026 · By · Wire by Fusion42

Published

8 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 8 September 2026 · Fusion42 review

Ascletis has initiated a Phase I clinical study in the United States for ASC36, an oral amylin receptor peptide agonist targeting obesity treatment.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Obesity drug developers can now see the US clinical trial pathway opening for oral amylin receptor peptides. You should review your own development timelines for potential US market entry or partnership opportunities.

◆ Coverage

1 source · 8 Sep 2026

◆ Related on Wire

◆ Topics

Biotechclinical-trialsobesity-treatmentbiotechoral-drugascletis